Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2023-11-01
سلاسل:	Frontiers in Oncology
الموضوعات:	clinical outcome toxicity low-and intermediate-risk radiotherapy prostate cancer stereotactic body radiation
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!